checkAd
    Startseite > Aktien > Tenaya Therapeutics > Nachrichten
    Tenaya Therapeutics Aktie
    4,2100
     
    USD
    +0,72 %
    +0,0300 USD
    Letzter Kurs 01.06.24 Nasdaq
    4,2100
     
    USD
    100 STK
    Geldkurs 31.05.24
    4,2200
     
    USD
    8.700 STK
    Briefkurs 31.05.24
    ISIN: US87990A1060 · WKN: A3CWF0 · SYM: TNYA · USA

    Neueste Nachrichten

    Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    14.05.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
    02.05.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    18.03.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
    18.03.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
    27.02.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
    26.02.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Announces Pricing of Underwritten Offering
    08.02.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
    21.11.23 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
    26.10.23 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
    09.10.23 · globenewswire · Tenaya Therapeutics
    Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
    05.10.23 · globenewswire · Tenaya Therapeutics